| 摘要 |
Compositions, formulations, methods, and systems for treating thyroid eye disease and related conditions (e.g., Grave's Ophthalmopathy). The methods described herein include administering, to a patient in need, systemic or lo cal beta adrenergic agonists (e.g., as an extended release crystalline micro particle suspension). The methods can further include administering a compou nd for reducing beta adrenergic receptor desensitization (e.g., a corticoste roid) prior to administering or coadministered with the beta adrenergic agon ist. The methods can also include locally administering to the eye an immuno suppressant agent (e.g., rapamycin) prior to administering a beta adrenergic agonist. The compositions described herein include ophthalmic pharmaceutica l formulations of beta adrenergic agonists in the form of extended release c rystalline microparticle suspensions or mixtures of the crystalline micropar ticle suspensions with beta adrenergic agonist solutions. The compositions a lso include ophthalmic formulations of a compound for reducing beta adrenerg ic receptor desensitization in the form of extended release crystalline micr oparticle suspensions. |
